AUSTIN, Texas — The country’s first peer-reviewed study of a COVID-19 treatment that transfuses blood plasma from recovered patients into critically ill patients shows 19 out of 25 patients improving, including 11 discharged from the hospital.
On March 28, Houston Methodist Hospital became the first academic medical center in the U.S. to transfuse plasma from recovered COVID-19 patients into two critically ill patients. Collaborators at The University of Texas at Austin developed an antibody test and selected recovered patients with the highest levels of antibody response for donation.
With no adverse side effects caused by the plasma transfusion, the study concluded that convalescent plasma therapy is a safe treatment option for patients with severe COVID-19 disease. To date, this is the largest cohort worldwide assessed